1. Adelaide Research & Scholarship

Search


Current filters:


Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-10 of 24 (Search time: 0.002 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2013PCR-mediated recombination can lead to artificial chimera formation, which may pose as BCR-ABL1 compound mutationsParker, W.; Phillis, S.; Yeung, D.; Hughes, T.; Scott, H.; Branford, S.; 55th American Society of Hematology Annual Meeting and Exhibition (07 Dec 2013 - 10 Dec 2013 : New Orleans, Louisiana)
2013Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: Evidence for site-specific skeletal effectsVandyke, K.; Fitter, S.; Drew, J.; Fukumoto, S.; Schultz, C.; Sims, N.; Yeung, D.; Hughes, T.; Zannettino, A.
2018Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cellsRoss, D.; Pagani, I.; Shanmuganathan, N.; Kok, C.; Seymour, J.; Mills, A.; Filshie, R.; Arthur, C.; Dang, P.; Saunders, V.; Braley, J.; Yong, A.; Yeung, D.; White, D.; Grigg, A.; Schwarer, A.; Branford, S.; Hughes, T.
2018Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: results from the Phase IIIb ENESTswift studyHiwase, D.; Tan, P.; D'Rozario, J.; Taper, J.; Powell, A.; Irving, I.; Wright, M.; Branford, S.; Yeung, D.; Anderson, L.; Gervasio, O.; Levetan, C.; Roberts, W.; Solterbeck, A.; Traficante, R.; Hughes, T.
2013Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CMLBranford, S.; Yeung, D.; Ross, D.; Prime, J.; Field, C.; Altamura, H.; Yeoman, A.; Georgievski, J.; Jamison, B.; Phillis, S.; Sullivan, B.; Briggs, N.; Hertzberg, M.; Seymour, J.; Reynolds, J.; Hughes, T.
2013Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER studyRoss, D.; Branford, S.; Seymour, J.; Schwarer, A.; Arthur, C.; Yeung, D.; Dang, P.; Goyne, J.; Slader, C.; Filshie, R.; Mills, A.; Vaz de Melo, J.; White, D.; Grigg, A.; Hughes, T.
2016TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapyNievergall, E.; Reynolds, J.; Kok, C.; Watkins, D.; Biondo, M.; Busfield, S.; Vairo, G.; Fuller, K.; Erber, W.; Sadras, T.; Grose, R.; Yeung, D.; Lopez, A.; Hiwase, D.; Hughes, T.; White, D.
2014Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 declineBranford, S.; Yeung, D.; Parker, W.; Roberts, N.; Purins, L.; Braley, J.; Altamura, H.; Yeoman, A.; Georgievski, J.; Jamison, B.; Phillis, S.; Donaldson, Z.; Leong, M.; Fletcher, L.; Seymour, J.; Grigg, A.; Ross, D.; Hughes, T.
2015KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategyYeung, D.; Tang, C.; Vidovic, L.; White, D.; Branford, S.; Hughes, T.; Yong, A.
2013BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistanceParker, W.; Yeoman, A.; Jamison, B.; Yeung, D.; Scott, H.; Hughes, T.; Branford, S.

Discover